In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot<sup>®</sup> ) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study.

Nakajima, Yuto; Takami, Eisuke; Nakano, Hirotoshi; Nogami, Keiji

In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot^® ) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study.

Nakajima, Yuto; Takami, Eisuke; Nakano, Hirotoshi; Nogami, Keiji.

Nakajima Y; Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
Takami E; Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara, Japan.
Nakano H; Medical Affairs Section, KM Biologics Co., Ltd, Kumamoto, Japan.
Nogami K; Medical Affairs Section, KM Biologics Co., Ltd, Kumamoto, Japan.

Haemophilia ; 28(5): e149-e152, 2022 09.

Article en En | MEDLINE | ID: mdl-35947585

Asunto(s)

Anticuerpos Biespecíficos; Hemofilia A; Anticuerpos Biespecíficos/farmacología; Anticuerpos Biespecíficos/uso terapéutico; Anticuerpos Monoclonales Humanizados; Factor VIII/uso terapéutico; Factor VIIa; Hemofilia A/tratamiento farmacológico; Humanos; Proyectos Piloto

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Hemofilia A Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Hemofilia A Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article